文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

高氧与高渗盐水治疗脓毒性休克患者(HYPERS2S):二乘二析因多中心随机临床试验

Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial.
PubMed 文献 · Lancet Respir Med · 2017-02-15
一句话结论脓毒性休克机械通气患者FiO2设为1.0诱导动脉高氧可能增加死亡风险,3%高渗盐水未改善生存。

HYPERS2S为法国22中心二乘二析因开放标签随机临床试验,纳入442例≥18岁机械通气脓毒性休克患者,比较FiO2 1.0(高氧)与目标SpO2 88-95%(正常氧)及3.0%高渗盐水与0.9%等渗盐水复苏。因安全原因提前终止。28天死亡率高氧组43%(93/217)vs正常氧组35%(77/217),HR 1.27(95%CI 0.94-1.72;p=0.12);高渗盐水组42%(89/214)vs等渗盐水组37%(81/220),HR 1.19(95%CI 0.88-1.61;p=0.25)。高氧组严重不良事件总体发生率85%(185例)vs正常氧组76%(165例),p=0.02;高氧组ICU获得性肌无力24例(11%)vs 13例(6%),p=0.06;肺不张26例(12%)vs 13例(6%),p=0.04。作者认为FiO2设为1.0诱导动脉高氧可能增加死亡风险,3%高渗盐水未改善生存。

要点

  • 脓毒性休克机械通气患者FiO2 1.0诱导高氧28天死亡43%(93/217)vs目标SpO2 88-95%的35%(77/217),HR 1.27(95%CI 0.94-1.72;p=0.12),未达统计学显著。
  • 高氧组严重不良事件总体发生率85%(185例)vs正常氧组76%(165例),p=0.02;肺不张高氧组12%(26例)vs正常氧组6%(13例),p=0.04。
  • ICU获得性肌无力高氧组11%(24例)vs正常氧组6%(13例),p=0.06;作者认为FiO2 1.0诱导动脉高氧可能增加死亡风险。
  • 3.0%高渗盐水280 mL团注复苏28天死亡42%(89/214)vs 0.9%等渗盐水37%(81/220),HR 1.19(95%CI 0.88-1.61;p=0.25),未改善生存。
  • 两种盐水组间严重不良事件无统计学差异(p=0.23)。

适用人群与场景

  • 年龄18岁及以上、脓毒性休克、接受机械通气的患者,来自法国22个中心。
  • 按是否存在急性呼吸窘迫综合征分层随机。

处置流程与药物剂量

  • 第一个24小时内机械通气FiO2设为1.0(高氧组)或FiO2调节至目标动脉血氧饱和度88-95%(正常氧组),开放标签。
  • 第一个72小时内液体复苏使用3.0%高渗盐水280 mL团注(高渗盐水组)或0.9%等渗盐水280 mL团注(等渗盐水组),双盲。

研究设计与关键结果

  • 二乘二析因、多中心、随机、开放标签临床试验,2012年11月3日至2014年6月13日纳入442例,随机分配至正常氧组(n=223)或高氧组(n=219)、等渗盐水组(n=224)或高渗盐水组(n=218),因安全原因提前终止。
  • 主要终点28天死亡率(意向性治疗人群,434例有记录):高氧组43%(93/217)vs正常氧组35%(77/217),HR 1.27(95%CI 0.94-1.72;p=0.12);高渗盐水组42%(89/214)vs等渗盐水组37%(81/220),HR 1.19(95%CI 0.88-1.61;p=0.25)。
  • 严重不良事件总体发生率:高氧组85%(185例)vs正常氧组76%(165例),p=0.02;ICU获得性肌无力高氧组11%(24例)vs正常氧组6%(13例),p=0.06;肺不张高氧组12%(26例)vs正常氧组6%(13例),p=0.04。
  • 两种盐水组间严重不良事件无统计学差异(p=0.23)。

证据类型、等级与局限

  • 研究类型:二乘二析因、多中心、随机、开放标签临床试验(HYPERS2S),注册号NCT01722422。
  • 因安全原因提前终止。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在脓毒性休克机械通气患者中,将FiO2设为1.0诱导动脉高氧可能增加死亡风险(作者认为),并伴随严重不良事件总体发生率、肺不张和ICU获得性肌无力数值上的增加。
  • 3.0%高渗盐水280 mL团注用于液体复苏未改善生存,两种盐水组间严重不良事件无统计学差异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: There is insufficient research into the use of mechanical ventilation with increased inspiratory oxygen concentration (FiO2) and fluid resuscitation with hypertonic saline solution in patients with septic shock. We tested whether these interventions are associated with reduced mortality.

METHODS: This two-by-two factorial, multicentre, randomised, clinical trial (HYPERS2S) recruited patients aged 18 years and older with septic shock who were on mechanical ventilation from 22 centres in France. Patients were randomly assigned 1:1:1:1 to four groups by a computer generated randomisation list stratified by site and presence or absence of acute respiratory distress syndrome by use of permuted blocks of random sizes. Patients received, in an open-labelled manner, mechanical ventilation either with FiO2 at 1·0 (hyperoxia) or FiO2 set to target an arterial haemoglobin oxygen saturation of 88-95% (normoxia) during the first 24 h; patients also received, in a double-blind manner, either 280 mL boluses of 3·0% (hypertonic) saline or 0·9% (isotonic) saline for fluid resuscitation during the first 72 h. The primary endpoint was mortality at day 28 after randomisation in the intention-to-treat population. This study was registered with ClinicalTrials.gov, number NCT01722422.

FINDINGS: Between Nov 3, 2012, and June 13, 2014, 442 patients were recruited and assigned to a treatment group (normoxia [n=223] or hyperoxia [n=219]; isotonic [n=224] or hypertonic [n=218]). The trial was stopped prematurely for safety reasons. 28 day mortality was recorded for 434 patients; 93 (43%) of 217 patients had died in the hyperoxia group versus 77 (35%) of 217 patients in the normoxia group (hazard ratio [HR] 1·27, 95% CI 0·94-1·72; p=0·12). 89 (42%) of 214 patients had died in the hypertonic group versus 81 (37%) of 220 patients in the isotonic group (HR 1·19, 0·88-1·61; p=0·25). We found a significant difference in the overall incidence of serious adverse events between the hyperoxia (185 [85%]) and normoxia groups (165 [76%]; p=0·02), with a clinically relevant doubling in the hyperoxia group of the number of patients with intensive care unit-acquired weakness (24 [11%] vs 13 [6%]; p=0·06) and atelectasis (26 [12%] vs 13 [6%]; p=0·04) compared with the normoxia group. We found no statistical difference for serious adverse events between the two saline groups (p=0·23).

INTERPRETATION: In patients with septic shock, setting FiO2 to 1·0 to induce arterial hyperoxia might increase the risk of mortality. Hypertonic (3%) saline did not improve survival.

FUNDING: The French Ministry of Health.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Asfar P, Schortgen F, Boisramé-Helms J, et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respir Med. 2017. PMID: 28219612. doi:10.1016/S2213-2600(17)30046-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。